A South African court has ordered pharmacy group iDexis to immediately stop selling semaglutide-based medicines after ruling in favour of pharmaceutical giant Novo Nordisk, intensifying regulatory scrutiny over the distribution of weight-loss and diabetes treatments in the country.
The legal action followed claims by Novo Nordisk, the manufacturer of globally recognised brands Ozempic and Wegovy, that iDexis had been supplying an estimated 84,500 units of semaglutide products each month without obtaining the necessary regulatory approval. The court’s decision reinforces the importance of compliance with pharmaceutical licensing requirements as demand for GLP-1 medicines continues to surge worldwide.
The ruling comes as regulators across several markets tighten oversight of compounded and unregistered versions of high-demand weight-loss medications. Brandspur Brand News understands that the case underscores growing concerns about patient safety, product quality, manufacturing standards and regulatory compliance as healthcare providers seek to meet rising demand for obesity and diabetes treatments.
Semaglutide-based medicines have witnessed exceptional global demand in recent years due to their effectiveness in managing type 2 diabetes and supporting weight management. However, supply shortages have also fuelled the emergence of compounded alternatives and unauthorised products, prompting increased legal and regulatory action from drug manufacturers and health authorities.
Novo Nordisk argued that the sale of semaglutide medicines without the required approvals could undermine established pharmaceutical standards designed to ensure product quality, safety and traceability. The company has continued to pursue legal measures in multiple jurisdictions to protect its intellectual property and safeguard patients from unapproved products entering the market.
The South African ruling is expected to have broader implications for pharmacies, healthcare providers and pharmaceutical distributors across Africa, where demand for GLP-1 therapies continues to rise. Industry observers believe the judgment could encourage stricter enforcement of medicine registration requirements while reinforcing confidence in approved pharmaceutical supply chains as obesity treatment becomes an increasingly important segment of the healthcare industry.
